The Motley Fool: Novo Nordisk has growth potential and dividend yield

There’s plenty of reason to remain bullish on Novo Nordisk. Even with the challenges it has faced recently, the company ...

Novo Nordisk chair, board members to quit after dispute with top shareholder

The chairman of Novo Nordisk and six other independent board members quit on Tuesday after a dispute with the company's ...

Long-time Novo Nordisk bull tapped to lead Wegovy maker’s IR division

Novo Nordisk (NVO) recruits top healthcare analyst Michael Novod, a long time bull of the company, as head of its investor ...
AOL

Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study

Novo Nordisk A/S (NYSE:NVO) presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025. The STEER ...
TipRanks on MSN

Novo Nordisk’s Wegovy Pregnancy Study: Safety Insights and Market Impact

Novo Nordisk (($NVO)) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is conducting a study titled ‘Wegovy® ...

Sell Novo Nordisk And Buy Viking Therapeutics

Viking Therapeutics is mispriced due to the successful but misunderstood clinical results of their oral GLP-1 treatment. Read ...

Novo Nordisk A/S (NVO)’s Top Investor Decides to Take Control of its Board, Reports Reuters

Novo Nordisk A/S (NYSE:NVO) is one of the Best Bargain Stocks to Buy in November. On October 22, Reuters reported that Novo ...

Novo Nordisk Shares Fell 5.6% After President Trump Commented on Future Price Cuts for Weight Loss Drugs. Should Investors Be Worried?

Novo Nordisk Shares Fell 5.6% After President Trump Commented on Future Price Cuts for Weight Loss Drugs. Should Investors Be ...